Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
McKesson
Colorcon
Dow
Baxter

Last Updated: April 1, 2020

DrugPatentWatch Database Preview

Litigation Details for CELGENE CORPORATION v. HETERO LABS LIMITED (D.N.J. 2017)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

CELGENE CORPORATION v. HETERO LABS LIMITED (D.N.J. 2017)

Docket   Start Trial Date Filed 2017-05-11
Court District Court, D. New Jersey Date Terminated
Cause 35:271 Patent Infringement Assigned To Esther Salas
Jury Demand None Referred To Michael A. Hammer
Parties APOTEX CORP.; APOTEX INC.; AUROBINDO PHARMA LIMITED; AUROBINDO PHARMA USA, INC.; AUROLIFE PHARMA LLC.; BRECKENRIDGE PHARMACEUTICAL, INC.; CELGENE CORPORATION; EUGIA PHARMA SPECIALTIES LIMITED; FAITH S. HOCHBERG; HETERO DRUGS LIMITED; HETERO LABS LIMITED; HETERO LABS LIMITED UNIT-V; HETERO USA, INC.; MELISSA E. FLAX; MYLAN INC.; MYLAN PHARMACEUTICALS, INC.; MYLAN, N.V.; NATCO PHARMA LIMITED; PHV JEANNA M. WACKER; TEVA PHARMACEUTICALS USA, INC.
Patents 10,006,091; 4,810,643; 4,999,291; 5,134,127; 5,580,755; 5,629,327; 5,635,517; 6,020,358; 6,045,501; 6,235,756; 6,281,230; 6,315,720; 6,316,471; 6,476,052; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 6,869,399; 6,908,432; 7,015,018; 7,119,106; 7,141,018; 7,189,740; 7,393,862; 7,435,745; 7,874,984; 7,959,566; 7,968,569; 8,008,006; 8,198,262; 8,315,886; 8,626,531; 8,673,939; 8,735,428; 8,828,427; 8,927,592; 9,109,020; 9,993,467
Attorneys ARNOLD B. CALMANN; BRIAN JOHN FORSATZ; CHARLES MICHAEL LIZZA; CHRISTINA LYNN SAVERIANO; CHRISTINE INTROMASSO GANNON; CHRISTOPHER TURCHIK JAGOE; COLLEEN M. MAKER; DAVID LEIGH MOSES; ELEONORE OFOSU-ANTWI; ERIC I. ABRAHAM; FAITH S. HOCHBERG; FRANK CHARLES CALVOSA; GREGORY D. MILLER; GURPREET SINGH WALIA; JAKOB BENJAMIN HALPERN; JENNA Z. GABAY; JOSEPH SCHRAMM , III; LIZA M. WALSH; MELISSA E. FLAX; MICHAEL CROSS; MICHELLE ERICA IRWIN; MONVAN HU; NICHOLAS ANTHONY LOCASTRO; ROBERT JOSEPH FETTWEIS; SARAH ANN SULLIVAN; WILLIAM C. BATON; YEVGENIA SHTILMAN KLEINER
Firms Carella, Byrne, Cecchi, Olstein, Brody & Agnello, P.C.; Carella, Byrne, Cecchi, Olstein, Brody & Agnello, PC; Christina Lynn Saveriano; Eric I. Abraham; Fisher Broyles LLP; Fisherbroyles, LLP; Fleming Ruvoldt PLLC; Hochberg Adr; Kirkland & Ellis LLP; Quinn Emanuel Uquhart & Sullival LLP; Quinn Emanuel Urquhart & Sullivan LLC; Quinn Emanuel Urquhart & Sullivan, LLP; Rivkin Radler LLP; Saiber, LLC; Saul Ewing Arnstein & Lehr LLP; Yevgenia Shtilman Kleiner
Link to Docket External link to docket
Small Molecule Drugs cited in CELGENE CORPORATION v. HETERO LABS LIMITED
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in CELGENE CORPORATION v. HETERO LABS LIMITED

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for CELGENE CORPORATION v. HETERO LABS LIMITED (D.N.J. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 168 Letter judgment of non-infringement of U.S. Patent No. 8,828,427 B2 (“’427 patent”). At the …judgment of non-infringement of U.S. Patent No. 8,828,427 (“’427 patent”); WHEREAS, on May 11…summary judgment of non-infringement of the ’427 patent (“Joint Letter concerning summary judgment…5 PageID: 4303 non-infringement of the ’427 patent by May 25, 2018 (17-3159 ECF No. 89, Text Order…summary judgment of non-infringement of the ’427 patent, and wish to join in the joint letter to be submitted External link to document
0000-00-00 211 Statement Evidence: • U.S. Patent No. 6,045,501 generally, including … • File History of United States Patent No. 6,045,501 …Evidence: • U.S. Patent No. 6,045,501 generally, including … • File History of U.S. Patent No. 6,045,501 at o Claims, Abstract, … • U.S. Patent No. 6,045,501: External link to document
0000-00-00 227 Exhibits 1-15 (Part 1) chronic myelocytic 230 and 5,635,517 to Muller et a!., in various U.S. patent leukemia, acute…organic acids. The acids that U.S. Pat. No. 5,635,517, the entirety of which is incorporated …botulinum toxin, inter- Nos. 6,281,230 and 5,635,517; U.S. publication nos. 2004/ feron…Claims of U.S. Patent Nos. 8,198,262 (“the ’262 patent”), 8,673,939 (“the ’939 patent”), 8,735,4288,735,428 (“the ’428 patent”), and 8,828,427 (“the ’427 patent”) (collectively, “the Patents-in-Suit”). External link to document
0000-00-00 237 Redacted Document non-infringement contentions for U.S. Patent No. 8,828,427 (the “’427 patent”). See No. 17-3387 at D.I. 216;…Disclosure Requirements of the Local Patent Rules The Local Patent Rules are “designed to require … for amendment pursuant to Local Patent Rule 3.7. If, however, they …found: (1) in Defendants’ own ANDAs and the ’427 patent’s publicly-available file history—both of which…necessary to analyze prejudice under the Local Patent Rules and this Court’s precedent. That prejudice External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
McKesson
Harvard Business School
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.